Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05180799 | A Phase 1/2 Study of BA3071 in Patients With Solid Tumors | PHASE1 | ACTIVE NOT_RECRUITING | 320 | — | — | Aug 3, 2022 | Jun 30, 2026 | Jun 15, 2025 | 12 | United States, Australia |
Phase 1: Safety Profile
Phase 1: Safety Profile
Phase 1 and 2: Safety Profile
Phase 2: Efficacy
| Arm | Type | Description |
|---|---|---|
| BA3071 | EXPERIMENTAL | Conditionally active biologic (CAB) antibody that binds to CTLA-4 |
| Combination Therapy | EXPERIMENTAL | Conditionally active biologic (CAB) antibody that binds to CTLA-4 with PD-1 inhibitor |
| Combination Therapy + Chemotherapy | EXPERIMENTAL | Conditionally active biologic (CAB) antibody that binds to CTLA-4 with PD-1 inhibitor + Chemotherapy |
| Neoadjuvant Combination Therapy + Chemotherapy | EXPERIMENTAL | Conditionally active biologic (CAB) antibody that binds to CTLA-4 with PD-1 inhibitor + Chemotherapy prior to surgical resection |
| Name | Type | Description |
|---|---|---|
| BA3071 | BIOLOGICAL | Conditionally active biologic (CAB) antibody that binds to CTLA-4 |
| Nivolumab | BIOLOGICAL | Humanized, immunoglobulin G4 (IgG4)-variant mAb against PD-1 |
| Pembrolizumab | BIOLOGICAL | Humanized antibody, immunoglobulin G4, with a variable region against the human PD-1 receptor |
| Pemetrexed (Alimta) | DRUG | pemetrexed with either cisplatin or carboplatin |
Inclusion Criteria: * Patients must have measurable disease. * Age ≥ 18 years * CLTA-4 blocking-antibody naïve * Adequate renal function * Adequate liver function * Adequate hematological function * Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Patients must have...